UPDATE : Monday, September 7, 2020
상단여백
‘Body fluid management using BCM improves kidney function’
“BCM (Body Composition Monitoring) can decide the way to manage fluid for d...
by Park Gi-taek  |  2017-09-12 08:26
라인
Healthcare benefits for immune checkpoint inhibitor Tecentrqi, unclear
Roche’s immune checkpoint inhibitor Tecentriq (Atezolizumab) might have a d...
by Park Gi-taek  |  2017-08-30 10:17
라인
When can we hear about the conquest of liver cancer?
Liver cancer, one of the four deadliest cancers in Korea, is called a "sile...
by Park Gi-taek  |  2017-08-29 07:00
라인
‘Let's protect patients until complete cure of hepatitis B comes’
"In the next 15 to 20 years, we will be able to cure chronic hepatitis B co...
by Park Gi-taek  |  2017-08-28 10:46
라인
Drugmakers cut entertainment expense due to anticorruption law
Almost a year after the Act on Prohibiting Illegal Solicitation, or “Kim Yo...
by Park Gi-taek  |  2017-08-25 16:27
라인
‘Moon Jae-in care’ keeps industry busy weighing bottom lines
After President Moon Jae-in announced a policy to drastically expand health...
by Park Gi-taek  |  2017-08-11 13:42
라인
New osteoporosis therapy causes curiosity about drug price
Ten years have passed since Amgen’s “Prolia,” the so-called first biologica...
by Park Gi-taek  |  2017-08-07 14:42
라인
‘Neither handouts nor patient complaints give insurance benefits to expensive drugs’
The countdown has begun to provide insurance benefits for the controversial...
by Park Gi-taek  |  2017-07-24 20:28
라인
CEOs of foreign pharmaceuticals don't seem to regard Korean employees as colleagues
In Korea, most people perceive multinational companies as “good workplaces....
by Park Gi-taek  |  2017-07-13 18:20
라인
Castleman’s disease patients suffer from high drug prices
Recently, some therapies for a small number of patients, including Ibrance ...
by Park Gi-taek  |  2017-07-11 17:00
라인
First patient resistant to Viread found in Korea
A Korean doctor has found patients who showed resistance to Viread (compoun...
by Park Gi-taek  |  2017-06-26 13:40
라인
Is personalized cancer treatment using NGS unavailable in Korea?
Is Korea still a long way from personalized cancer treatment using next gen...
by Park Gi-taek  |  2017-06-22 18:19
라인
‘Korean version of NOAC guidelines may come out before long’
Since the introduction of Non-Vitamin K Antagonist Oral Anticoagulant (NOAC...
by Park Gi-taek  |  2017-06-20 17:52
라인
‘Early diagnosis necessary for treating rare Gaucher's disease’
There are about 7,000 rare diseases found worldwide, but a fraction of them...
by Park Gi-taek  |  2017-06-19 20:22
라인
Introduction of DAA changed treatment of Hepatitis C
Since the approval of the combination therapy Daklinza-Sunvepra (Daksun the...
by Park Gi-taek  |  2017-06-07 16:43
라인
Gilead’s new hepatitis B therapy in controversy due to side effects
Could it be that Gilead’s new hepatitis B medicine Vemlidy (compound tenofo...
by Park Gi-taek  |  2017-05-31 17:04
라인
Gilead Sciences keeps on rolling in Korea: Why?
When the news spread six years ago that Gilead Sciences길리어드 would enter the...
by Park Gi-taek  |  2017-05-11 14:52
라인
Can Jardiance threaten Forxiga's dominance in treating diabetes?
Korean regulators have officially recognized the effect of SGLT-2 (sodiumgl...
by Park Gi-taek  |  2017-05-04 13:30
라인
‘We must move beyond completely curing Hepatitis C to eradicating it’
From the end of 2015 to 2016, mass infections of hepatitis C occurred at th...
by Park Gi-taek  |  2017-04-18 14:47
라인
Will post-mass infection anti-HCV measures prove to be sufficient?
From the end of 2015 to 2016, mass infections of hepatitis C occurred at th...
by Park Gi-taek  |  2017-04-17 16:49
여백
여백
여백
Back to Top